# DAYBUE (trofinetide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/trofinetide

> The FDA approved DAYBUE (trofinetide), sponsored by ACADIA PHARMACEUTICALS INC (ACAD), on Dec 2025 for Rett syndrome.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | DAYBUE (trofinetide) |
| Codes |  |
| Sponsor | ACADIA PHARMACEUTICALS INC (ACAD) https://sec-api.dev/companies/acad/catalysts |
| Indications | [rett syndrome](https://sec-api.dev/indications/rett-syndrome), rett syndrome in adult and pediatric patients two years of age and older |
| Modality | peptide |
| FDA designations | fast track, orphan, priority review |

## Timeline

### Mar 2023: FDA approval

- Status: completed, approved. Date confidence: month. Indication: Rett syndrome.
- First seen 2025-02-27, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-447794): "In March 2023, the FDA approved the Company's second drug, DAYBUE® (trofinetide), for the treatment of Rett syndrome." https://www.sec.gov/Archives/edgar/data/1070494/000119312526447794/acad-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-447794): "The FDA approved DAYBUE in March 2023 for the treatment of Rett syndrome and we launched the product in the United States in April 2023." https://www.sec.gov/Archives/edgar/data/1070494/000119312526447794/acad-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-333243): "In March 2023, the FDA approved the Company's second drug, DAYBUE® (trofinetide), for the treatment of Rett syndrome." https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-333243): "The FDA approved DAYBUE in March 2023 for the treatment of Rett syndrome and we launched the product in the United States in April 2023." https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-209731): "In March 2023, the FDA approved the Company's second drug, DAYBUE® (trofinetide), for the treatment of Rett syndrome." https://www.sec.gov/Archives/edgar/data/1070494/000119312526209731/acad-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-209731): "The FDA approved DAYBUE in March 2023 for the treatment of Rett syndrome and we launched the product in the United States in April 2023." https://www.sec.gov/Archives/edgar/data/1070494/000119312526209731/acad-20260331.htm
- SEC Form 10-K (accession 0001193125-26-072519): "The FDA approved DAYBUE in March 2023 for the treatment of Rett syndrome and we launched the product in the United States in April 2023." https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm
- SEC Form 10-K (accession 0001193125-26-072519): "In March 2023, the FDA approved the Company's second drug, DAYBUE® (trofinetide), for the treatment of Rett syndrome." https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-267453): "In March 2023, the FDA approved the Company's second drug, DAYBUE (trofinetide), for the treatment of Rett syndrome." https://www.sec.gov/Archives/edgar/data/1070494/000119312525267453/acad-20250930.htm
- SEC Form 10-Q (accession 0001193125-25-267453): "The FDA approved DAYBUE in March 2023 for the treatment of Rett syndrome and we launched the product in the United States in April 2023." https://www.sec.gov/Archives/edgar/data/1070494/000119312525267453/acad-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104295): "In March 2023, the FDA approved the Company's second drug, DAYBUE (trofinetide), for the treatment of Rett syndrome." https://www.sec.gov/Archives/edgar/data/1070494/000095017025104295/acad-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-104295): "The FDA approved DAYBUE in March 2023 for the treatment of Rett syndrome and we launched the product in the United States in April 2023." https://www.sec.gov/Archives/edgar/data/1070494/000095017025104295/acad-20250630.htm

### Dec 2025: FDA approval

- Status: completed, approved. Date confidence: month. Indication: Rett syndrome.
- First seen 2026-02-26, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-447794): "The FDA approved DAYBUE STIX in December 2025 for the treatment of Rett syndrome and we made the product available on a limited basis in the first quarter of 2026 followed by a broader launch in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1070494/000119312526447794/acad-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-333243): "The FDA approved DAYBUE STIX in December 2025 for the treatment of Rett syndrome and we made the product available on a limited basis in the first quarter of 2026 followed by a broader launch in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-209731): "The FDA approved DAYBUE STIX in December 2025 for the treatment of Rett syndrome and we made the product available on a limited basis in the first quarter of 2026 followed by a broader launch in early Q2 2026." https://www.sec.gov/Archives/edgar/data/1070494/000119312526209731/acad-20260331.htm
- SEC Form 10-K (accession 0001193125-26-072519): "In December 2025, we received FDA approval for DAYBUE STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older." https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm
- SEC Form 10-K (accession 0001193125-26-072519): "The FDA approved DAYBUE STIX in December 2025 for the treatment of Rett syndrome and we made the product available on a limited basis in the first quarter of 2026, with a broader launch planned for Q2 2026." https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm

### Nov 2026: topline data readout

- Status: scheduled. Date confidence: month.
- First seen 2026-05-06, last confirmed 2026-05-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-209253): "Accelerated enrollment in the trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026 timeframe." https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-ex99_1.htm

## Same indication

- [Syndrome](https://sec-api.dev/pdufa/syndrome) (NGNE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/trofinetide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DAYBUE (trofinetide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/trofinetide

```bibtex
@misc{secapidev_pdufa_trofinetide_20261116,
  title        = {DAYBUE (trofinetide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/trofinetide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_trofinetide_20261116","title":"DAYBUE (trofinetide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/trofinetide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
